Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
March 04, 2025 14:06 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
Irazú Oncology Secures Bridge Funding, Expands Leadership Team and Facilities
March 04, 2025 08:30 ET
|
Irazu Oncology
Dr. Mayukh Das, joined Irazú as CMO, bringing extensive oncology drug development experience from leadership roles at global pharmaceutical companies.
Tumor Ablation Market to Reach $7.5 billion, Globally, by 2035 at 13.6% CAGR: Allied Market Research
March 04, 2025 06:30 ET
|
Allied Market Research INC
Wilmington, Delaware, March 04, 2025 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Tumor Ablation Market by Technology (Radiofrequency Ablation, Microwave Ablation,...
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
February 27, 2025 16:05 ET
|
Cardiff Oncology, Inc.
- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) - - Priced oversubscribed $40...
KFNCCC Welcomes Georgina Rodríguez's Visit to Support Young Cancer Patients
February 27, 2025 06:51 ET
|
King Faisal Specialist Hospital & Research Centre
KFNCCC Welcomes Georgina Rodríguez's Visit to Support Young Cancer Patients
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
February 26, 2025 16:02 ET
|
Revolution Medicines, Inc.
Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data...
Rakovina Therapeutics and Variational AI Strengthen Partnership
February 26, 2025 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response...
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
February 25, 2025 08:30 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase...
Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update
February 25, 2025 07:00 ET
|
Medicenna Therapeutics Corp.
MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity MDNA11 has shown durable single agent activity, with a...